Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is expected to be posting its Q4 24/25 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Dr. Reddy's Laboratories to post earnings of $0.20 per share and revenue of $83.70 billion for the quarter.
Dr. Reddy's Laboratories Price Performance
Shares of NYSE:RDY traded up $0.36 on Friday, reaching $13.54. The company's stock had a trading volume of 601,189 shares, compared to its average volume of 1,485,766. The company has a market cap of $11.30 billion, a P/E ratio of 21.56 and a beta of 0.33. The company has a 50-day simple moving average of $13.28 and a 200 day simple moving average of $14.10. Dr. Reddy's Laboratories has a 52-week low of $12.26 and a 52-week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.
Analyst Ratings Changes
Separately, StockNews.com raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday.
Get Our Latest Report on RDY
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Articles
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
